Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - HEALTHSOUTH CORPexhibit99_1.htm


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (date of earliest event reported): June 23, 2010
 
HealthSouth Corporation
 
(Exact Name of Registrant as Specified in its Charter)
 
Delaware
(State or Other Jurisdiction of Incorporation)
 
001-10315
63-0860407
(Commission File Number)
(I.R.S. Employer
Identification No.)
 
3660 Grandview Parkway, Suite 200, Birmingham, Alabama 35243
(Address of Principal Executive Officers, Including Zip Code)
 
(205) 967-7116
(Registrant’s telephone number)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 



 
 

 

ITEM 7.01. Regulation FD Disclosure.
 
HealthSouth Corporation (“HealthSouth” or the “Company”) will participate in the 2010 Wells Fargo Securities Healthcare Conference in Boston, Massachusetts on June 23-24, 2010. As part of this conference, representatives of HealthSouth will make a presentation on June 24, 2010 at 1:30 p.m. ET using the slides attached to this Current Report on Form 8-K as Exhibit 99.1. The presentation will address, among other things, the Company’s strategy, objectives, financial performance, and development process and discuss industry trends and dynamics. The presentation will be webcast live and will be available at http://investor.healthsouth.com by clicking on an available link.
 
While the format of certain slides may have changed, the slide presentation attached to this Current Report on Form 8-K as Exhibit 99.1 contains substantially the same information as previously provided in the Current Reports on Form 8-K dated May 19, 2010 and June 9, 2010.
 
In the slide presentation attached to this Current Report on Form 8-K as Exhibit 99.1, the Company provides the following brief update on its operational performance:

 
Good performance through May compared to same period last year
 
o  
Volume: solid in April, soft in May, appears to be rebounding in June;
 
o  
Expenses: continue to be aggressively managed; and
 
o  
Pricing: favorable trend.
 
In the slide presentation, the Company also notes it began integration of the newly acquired Desert Canyon Rehabilitation Hospital on June 1, 2010 and the newly built hospital in Loudoun County, Virginia began accepting patients on June 14, 2010.
 
The Company uses “same store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same store comparisons are calculated based on hospitals open throughout both the full current periods and throughout the full prior periods presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations.
 
The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The furnishing of this report is not intended to constitute a determination by the Company that the information is material or that the dissemination of the information is required by Regulation FD.
 
Note Regarding Presentation of Non-GAAP Financial Measures
 
The financial data contained in the presentation include non-GAAP financial measures, including the Company’s leverage ratio and Adjusted Consolidated EBITDA. The Company’s leverage ratio is defined in its credit agreement as the ratio of consolidated total debt to Adjusted Consolidated EBITDA for the trailing four quarters. The Company continues to believe both its leverage ratio and Adjusted Consolidated EBITDA as defined in its credit agreement are measures of its ability to service its debt and its ability to make capital expenditures.
 
The Company uses Adjusted Consolidated EBITDA on a consolidated basis as a liquidity measure. The Company believes this financial measure on a consolidated basis is important in analyzing its liquidity because it is the key component of certain material covenants contained within the Company’s credit agreement, which is discussed in more detail in Note 8, Long-term Debt, to the consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2009 (the “2009 Form 10-K”). These covenants are material terms of the credit agreement, and the credit agreement represents a substantial portion of the Company’s capitalization.
 
 
 

 
Non-compliance with these financial covenants under the credit agreement – its interest coverage ratio and its leverage ratio – could result in the Company’s lenders requiring the Company to immediately repay all amounts borrowed. If the Company anticipated a potential covenant violation, it would seek relief from its lenders, which would have some cost to the Company, and such relief might not be on terms favorable to those in the Company’s existing credit agreement. In addition, if the Company cannot satisfy these financial covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted Consolidated EBITDA is critical to the Company’s assessment of its liquidity.
 
In general terms, the definition of Adjusted Consolidated EBITDA, per the credit agreement, allows the Company to add back to or subtract from consolidated net income unusual non-cash or non-recurring items. These items include, but may not be limited to, (1) amounts associated with government, class action, and related settlements, (2) amounts related to discontinued operations and closed locations, (3) charges in respect of professional fees for reconstruction and restatement of financial statements, including fees paid to outside professional firms for matters related to internal controls and legal fees for continued litigation and support matters discussed in Note 22, Settlements, and Note 23, Contingencies and Other Commitments, to the consolidated financial statements accompanying the 2009 Form 10-K and Note 8, Contingencies, to the condensed consolidated financial statements included in Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2010 (the “March 2010 Form 10-Q”), (4) stock-based compensation expense, (5) net investment and other income (including interest income), and (6) fees associated with the Company’s divestiture activities.
 
In accordance with the credit agreement, the Company is allowed to add certain other items to the calculation of Adjusted Consolidated EBITDA, and there may also be certain other deductions required. This includes the interest income associated with income tax recoveries, as discussed in Note 19, Income Taxes, to the consolidated financial statements included in the 2009 Form 10-K. In addition, the Company is allowed to add non-recurring cash gains, such as the cash proceeds from the UBS Settlement (see Note 22, Settlements, to the consolidated financial statements included in the 2009 Form 10-K) to the calculation of Adjusted Consolidated EBITDA. As these adjustments may not be indicative of the Company’s ongoing performance, they have been excluded from Adjusted Consolidated EBITDA presented herein and included in the slide presentation attached as Exhibit 99.1.
 
However, Adjusted Consolidated EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America (“GAAP”), and the items excluded from Adjusted Consolidated EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted Consolidated EBITDA should not be considered a substitute for net income or cash flows from operating, investing, or financing activities. The Company reconciles Adjusted Consolidated EBITDA to net income, which reconciliation is set forth in the slide presentation attached as Exhibit 99.1, and to net cash provided by operating activities, which reconciliation is set forth below. Because Adjusted Consolidated EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted Consolidated EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in the 2009 Form 10-K.
 
The Company also uses adjusted income from continuing operations and the related per share amounts, which amounts are also referred to as “adjusted earnings per share,” as analytical indicators to assess its performance. Management believes the presentation of adjusted income from continuing operations and the related per share amounts provides useful information to management and investors about the Company’s operating business before taking into account certain items that are non-operational or infrequent in nature. These measures are not defined measures of financial performance under GAAP and should not be considered as alternatives to net income and net income per share attributable to HealthSouth common shareholders. Because these measures are not measures determined in accordance with GAAP and are susceptible to varying calculations, they may not be comparable to other similarly titled measures presented by other companies. See the consolidated statements of operations included in the 2009 Form 10-K and the condensed consolidated statements of operations included in the March 2010 Form 10-Q for the GAAP measures of net income, income from continuing operations, and basic and diluted earnings per common share. A reconciliation of net income to adjusted income from continuing operations, and the related per share amounts, is included in the slide presentation attached as Exhibit 99.1.
 
 
 

 
The Company also uses adjusted free cash flow as an analytical indicator to assess its performance. Management believes the presentation of adjusted free cash flow provides investors an efficient means by which they can evaluate the Company’s capacity to reduce debt and pursue development activities. The calculation of adjusted free cash flow is included in the slide presentation attached as Exhibit 99.1. This measure is not a defined measure of financial performance under GAAP and should not be considered as an alternative to net cash provided by operating activities. The Company’s definition of adjusted free cash flow is limited and does not represent residual cash flows available for discretionary spending. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. See the consolidated statements of cash flows included in the 2009 Form 10-K and the condensed consolidated statements of cash flows included in the March 2009 Form 10-Q for the GAAP measures of cash flows from operating, investing, and financing activities. A reconciliation of net cash provided by operating activities to Adjusted Consolidated EBITDA and adjusted free cash flow is presented below (in millions).
 
Reconciliation of Net Cash Provided by Operating Activities to Adjusted Consolidated EBITDA
 

   
Three Months Ended
   
Year Ended
   
Year Ended
 
   
March 31,
   
December 31,
   
December 31,
 
   
2010
   
2009
   
2009
   
2008
 
                         
Net cash provided by operating activities
  $ 84.8     $ 183.1     $ 406.1     $ 227.2  
Provision for doubtful accounts
    (6.9 )     (7.8 )     (33.1 )     (27.0 )
Professional fees-accounting, tax, and legal
    2.9       4.8       8.8       44.4  
Interest expense and amortization of debt
                               
discounts and fees
    30.5       34.4       125.8       159.5  
UBS Settlement proceeds, gross
    -       (100.0 )     (100.0 )     -  
Equity in net income of nonconsolidated affiliates
    2.6       2.5       4.6       10.6  
Net income attributable to noncontrolling
                               
   interests in continuing operations
    (9.8 )     (8.3 )     (33.4 )     (29.8 )
Amortization of debt discounts and fees
    (1.7 )     (1.6 )     (6.6 )     (6.5 )
Distributions from nonconsolidated affiliates
    (2.1 )     (1.5 )     (8.6 )     (10.9 )
Current portion of income tax expense (benefit)
    2.1       (0.3 )     (7.3 )     (73.8 )
Change in assets and liabilities
    0.7       (9.0 )     0.8       53.1  
Change in government, class action, and
                               
related settlements liability
    0.8       1.7       11.2       7.4  
Other operating cash used in (provided by)
                               
discontinued operations
    2.2       0.5       13.5       (11.4 )
Other
    0.3       (0.1 )     1.2       (1.6 )
Adjusted Consolidated EBITDA
  $ 106.4     $ 98.4     $ 383.0     $ 341.2  

 
 

 
Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow
 

   
Three Months
   
Three Months
   
Year
   
Year
 
   
Ended
   
Ended
   
Ended
   
Ended
 
   
March 31,
   
March 31,
   
December 31,
   
December 31,
 
   
2010
   
2009
   
2009
   
2008
 
Net cash provided by operating activities
  $ 84.8     $ 183.1     $ 406.1     $ 227.2  
Impact of discontinued operations
    2.2       0.5       13.5       (11.4 )
Net cash provided by operating
                               
activities of continuing operations
    87.0       183.6       419.6       215.8  
Capital expenditures for maintenance
    (5.6 )     (7.5 )     (34.1 )     (42.6 )
Net settlements on interest rate swaps
    (11.9 )     (8.5 )     (42.2 )     (20.7 )
Dividends paid on convertible perpetual
                               
preferred stock
    (6.5 )     (6.5 )     (26.0 )     (26.0 )
Distributions paid to noncontrolling interests
                               
of consolidated affiliates
    (11.1 )     (8.5 )     (32.7 )     (33.4 )
Non-recurring items:
                               
UBS Settlement proceeds, less fees
                               
to derivative plaintiffs' attorneys
    -       (73.8 )     (73.8 )     -  
Income tax refunds related to prior periods
    (6.6 )     (49.0 )     (63.7 )     (90.4 )
Cash paid for:
                               
Professional fees - accounting, tax,
                               
and legal
    2.9       4.8       15.3       18.2  
Government, class action, and related
                               
settlements
    0.8       1.7       11.2       7.4  
Adjusted free cash flow
  $ 49.0     $ 36.3     $ 173.6     $ 28.3  

For the three months ended March 31, 2010, net cash used in investing activities was $26.2 million and resulted primarily from capital expenditures, net settlement payments related to interest rate swaps, and an increase in restricted cash offset by proceeds from the sale of the Company’s hospital in Baton Rouge, Louisiana. Net cash used in financing activities during the three months ended March 31, 2010 was $22.7 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, dividends paid on the Company’s convertible perpetual preferred stock, and net debt payments.
 
For the three months ended March 31, 2009, net cash used in investing activities was $30.2 million and resulted primarily from capital expenditures and net settlement payments related to an interest rate swap. Net cash used in financing activities during the three months ended March 31, 2009 was $94.4 million and resulted primarily from net debt payments made during the period, as well as distributions paid to noncontrolling interests of consolidated affiliates and dividends paid on the Company’s convertible perpetual preferred stock.
 
For the year ended December 31, 2009, net cash used in investing activities was $133.0 million and resulted primarily from capital expenditures and net settlement payments related to interest rate swaps. Net cash used in financing activities during the year ended December 31, 2009 was $224.3 million and resulted primarily from net debt payments made during the period, as well as distributions paid to noncontrolling interests of consolidated affiliates, dividends paid on the Company’s convertible perpetual preferred stock, and debt amendment and issuance costs.
 
For the year ended December 31, 2008, net cash used in investing activities was $40.0 million and resulted primarily from capital expenditures, including expenditures associated with development activities, and net settlement payments related to an interest rate swap offset by proceeds from asset disposals, including the Company’s corporate campus. Net cash used in financing activities during the year ended December 31, 2008 was $176.0 million and resulted primarily from net debt payments made during the period, as well as distributions paid to noncontrolling interests of consolidated affiliates and dividends paid on the Company’s perpetual preferred stock, offset by proceeds from the issuance of common stock.
 
 
 

 
Forward-Looking Statements
 
The information contained in this Current Report on Form 8-K and the slide presentation attached as Exhibit 99.1 includes certain estimates, projections, and other forward-looking information that reflect the Company’s current views with respect to future events and financial performance. These estimates, projections, and other forward-looking information are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual results, and those differences may be material.
 
There can be no assurance that any estimates, projections, or forward-looking information will be realized. All such estimates, projections, and forward-looking information speak only as of the date hereof. The Company undertakes no duty to publicly update or revise the information contained herein or in the slide presentation.
 
The slide presentation also includes estimates and projections published by the Centers for Medicare and Medicaid Services (“CMS”). HealthSouth is not able to verify those estimates or projections or the detailed calculations thereof by CMS which are not made public. Any changes or errors in those calculations, among other uncertainties such as those referred to below and changes in CMS’s own rules and policies, could cause actual results to differ materially from CMS’s projections. Furthermore, the Company does not believe that CMS’s numbers are consistent with financial reporting results. CMS data and projections should not be used as an indication of financial performance.
 
You are cautioned not to place undue reliance on the estimates, projections, and other forward-looking information in this Current Report on Form 8-K or the slide presentation as they are based on current expectations and general assumptions and are subject to various risks, uncertainties, and other factors, including those set forth in the 2009 Form 10-K, the March 2010 Form 10-Q, and other documents the Company previously filed with the SEC, many of which are beyond the Company’s control. These factors may cause actual results to differ materially from the views, beliefs and estimates expressed herein.
 
ITEM 9.01. Financial Statements and Exhibits
 
(d)           Exhibits
 
 
99.1
Slide presentation of HealthSouth Corporation used in connection with the Company’s June 24, 2010 presentation at the 2010 Wells Fargo Securities Healthcare Conference.
 

 

 
 

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
 

  HEALTHSOUTH Corporation  
       
 
By:
/s/     JOHN P. WHITTINGTON  
    Name:       John P. Whittington  
    Title:         Executive Vice President, General Counsel, and Corporate Secretary  
       
Dated: June 23, 2010